CLOSE×

UKONIQ is a prescription medicine used to treat adults with marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least 1 certain type of prior treatment and follicular lymphoma (FL) when the disease has come back or did not respond to treatment and who have received at least 3 prior treatments. It is not known if UKONIQ is safe and effective in children.

UKONIQ was approved through a faster FDA review process based on the percentage of patients whose tumor size shrank or disappeared after treatment. There is an ongoing study to confirm the benefit of UKONIQ for these uses.

IMPORTANT SAFETY INFORMATION

UKONIQ can cause serious side effects, including:

  • Infections. UKONIQ can cause serious infections that may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, flu-like symptoms, or any other signs of infection during treatment with UKONIQ.
  • Low white blood cell count (neutropenia). Neutropenia is common with UKONIQ treatment and can sometimes be serious. Your healthcare provider will check your blood counts regularly during treatment with UKONIQ. Tell your healthcare provider right away if you have a fever or any signs of infection during treatment with UKONIQ.
  • Diarrhea or inflammation of your intestine (colitis). Diarrhea is common during UKONIQ treatment and can sometimes be serious. Tell your healthcare provider right away if you have diarrhea that does not go away or worsening diarrhea, stool with mucus or blood, or if you have severe stomach area (abdominal) pain during treatment with UKONIQ. Drink plenty of fluids during treatment with UKONIQ to help prevent dehydration from diarrhea.
  • Liver problems. Abnormal liver function blood test results are common and can sometimes be serious. Your healthcare provider will do blood tests before and during your treatment with UKONIQ to check for liver problems. Tell your healthcare provider right away if you have any of the following symptoms of liver problems:
    Yellowing of your skin or the white part of your eyes (jaundice)
    Dark or brown (tea colored) urine
    Pain in the upper right side of your stomach area (abdomen)
    Bleeding or bruising more easily than normal
  • Severe skin reactions. Rashes and other skin reactions are common with UKONIQ treatment and can sometimes be severe and lead to death. Tell your healthcare provider right away if you get a new or worsening skin rash or other signs of a severe skin reaction during treatment with UKONIQ, including:
    Painful sores or ulcers on your skin, lips, or in your mouth
    Rash with blisters or peeling skin
    Rash with itching
    Rash with fever

    If you have any of the above serious side effects during treatment with UKONIQ, your doctor may completely stop your treatment, stop your treatment for a period of time, or change your dose of UKONIQ.

    Before starting UKONIQ, tell your healthcare provider about all of your medical conditions, including if you:

    Have an infection
    Have abdominal or intestinal problems
    Have liver problems
    Are allergic to FD&C Yellow No. 5 (tartrazine) or aspirin. UKONIQ tablets contain FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain people, especially people who also have an allergy to aspirin.
    Are pregnant or plan to become pregnant. UKONIQ can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with UKONIQ.
    Females and males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment with UKONIQ and for 1 month after the last dose of UKONIQ. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you or your partner become pregnant or think you are pregnant during treatment with UKONIQ.
    Are breastfeeding or plan to breastfeed. It is not known if UKONIQ passes into your breast milk. Do not breastfeed during treatment with UKONIQ and for 1 month after the last dose of UKONIQ.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    The most common side effects of UKONIQ include:

    Changes in certain kidney function blood tests
    Tiredness
    Nausea
    Muscle or bone pain
    Low red blood cell count (anemia)
    Low platelet count
    Upper respiratory tract infection
    Vomiting
    Abdominal pain
    Decreased appetite

    These are not all the possible side effects with UKONIQ. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

  • For important risk and use information about UKONIQ, please see the full Product Information.
What is UKONIQ (umbralisib)?
  • UKONIQ is a prescription medicine used to treat adults with:
    Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least 1 certain type of prior treatment
    Follicular lymphoma (FL) when the disease has come back or did not respond to treatment and who have received at least 3 prior treatments
    It is not known if UKONIQ is safe and effective in children.
  • UKONIQ was approved through a faster FDA review process based on the percentage of patients whose tumor size shrank or disappeared after treatment. There is an ongoing study to confirm the benefit of UKONIQ for these uses.

Introducing

TG Therapeutics has created TG Patient Support to provide you with resources and information to help you access and manage your medication, including:

Insurance support, including verifying your insurance coverage and how much you may need to pay for your medication
Information about financial assistance options for eligible patients
Educational support to help you understand your UKONIQ prescription and prepare for your therapy based on the treatment plan that you and your healthcare provider have established

TG Patient Support offers you a personalized dedicated care team made up of TG Patient Support nurses and case managers

Who is our dedicated care team?

Icon representing a TG Patient Support Nurse

TG PATIENT SUPPORT NURSES


TG Patient Support nurses will provide you with information and education about your prescribed medication, UKONIQ.

Icon representing a TG Patient Support Case Manager

CASE MANAGERS


Your dedicated case manager, who has extensive insurance expertise, will be your primary point of contact to help you understand your current insurance coverage, how much your prescription will cost you, and your eligibility for financial assistance programs.

How can our program help you?

Icon representing a TG Financial Assistance
Icon representing a starting flag

TG FINANCIAL ASSISTANCE PROGRAMS


    Icon of a checkbox

    Commercial co-pay program

  • If you have commercial health insurance (also referred to as private insurance) coverage, you may qualify for the commercial co-pay program. Eligible patients will pay as little as $5 per prescription. See full Terms and Conditions

    Enroll Now
  • Enroll Now >
    Icon of a checkbox

    Independent charitable organizations

  • If you have state or federally funded insurance coverage from Medicare or Medicaid, but still have trouble paying for your prescriptions, TG Therapeutics can help provide you with a list of financial assistance options from independent charitable organizations

  • Icon of a checkbox

    Quick Start and Bridge programs

  • If there is a delay or lapse in your insurance coverage, your prescriber may request temporary assistance through our Quick Start and Bridge programs

  • Icon of a checkbox

    Patient Assistance Program

  • If you do not have insurance coverage or if you are underinsured, you may qualify for the Patient Assistance Program if you meet certain financial eligibility criteria*

  • *Patients must meet certain eligibility criteria to qualify for the Patient Assistance Program. Eligible patients must be uninsured or underinsured with an annual family gross income equal to or less than 600% of the current federal poverty level.

Icon representing a starting flag

GETTING STARTED WITH UKONIQ


    Icon representing an enrollment form

    STEP 1: Enroll

  • Enroll in Patient Support or ask your healthcare provider about signing up. Both you and your healthcare provider will need to fill out and sign portions of the enrollment form

  • Icon representing the introductory call with your Case Manager

    STEP 2: Introductory call

  • Your dedicated case manager will reach out to explain what to expect for enrolling in the program

  • Icon representing a TG Financial Assistance

    STEP 3: Checking your insurance coverage for UKONIQ

  • Your case manager will call your insurance company to gather coverage details for your prescribed medication, UKONIQ. They will also help you understand your eligibility for financial assistance options

  • Icon representing a pill bottle

    STEP 4: Your prescription is filled

  • There are 2 main ways you may receive UKONIQ:

    -

    Your physician may dispense the medication in the office

    -

    Your physician may submit your prescription to a specialty pharmacy, who will deliver medication straight to your home

  • Icon representing a support package being sent from TG Therapeutics

    STEP 5: Product and disease education

  • You may receive information and educational support about your diagnosis and UKONIQ from your TG Patient Support nurse

ADDITIONAL RESOURCES TO HELP YOU NAVIGATE YOUR OWN UNIQUE JOURNEY

TG PATIENT SUPPORT BROCHURE

IMPORTANT PRODUCT INFORMATION

What is UKONIQ (umbralisib)?

UKONIQ is a prescription medicine used to treat adults with:

Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least 1 certain type of prior treatment
Follicular lymphoma (FL) when the disease has come back or did not respond to treatment and who have received at least 3 prior treatments

It is not known if UKONIQ is safe and effective in children.

UKONIQ was approved through a faster FDA review process based on the percentage of patients whose tumor size shrank or disappeared after treatment. There is an ongoing study to confirm the benefit of UKONIQ for these uses.

Important Safety Information

  • UKONIQ can cause serious side effects, including:
  • Infections. UKONIQ can cause serious infections that may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, flu-like symptoms, or any other signs of infection during treatment with UKONIQ.
  • Low white blood cell count (neutropenia). Neutropenia is common with UKONIQ treatment and can sometimes be serious. Your healthcare provider will check your blood counts regularly during treatment with UKONIQ. Tell your healthcare provider right away if you have a fever or any signs of infection during treatment with UKONIQ.
  • Diarrhea or inflammation of your intestine (colitis). Diarrhea is common during UKONIQ treatment and can sometimes be serious. Tell your healthcare provider right away if you have diarrhea that does not go away or worsening diarrhea, stool with mucus or blood, or if you have severe stomach area (abdominal) pain during treatment with UKONIQ. Drink plenty of fluids during treatment with UKONIQ to help prevent dehydration from diarrhea.
  • Liver problems. Abnormal liver function blood test results are common and can sometimes be serious. Your healthcare provider will do blood tests before and during your treatment with UKONIQ to check for liver problems. Tell your healthcare provider right away if you have any of the following symptoms of liver problems:
    Yellowing of your skin or the white part of your eyes (jaundice)
    Dark or brown (tea colored) urine
    Pain in the upper right side of your stomach area (abdomen)
    Bleeding or bruising more easily than normal
  • Severe skin reactions. Rashes and other skin reactions are common with UKONIQ treatment and can sometimes be severe and lead to death. Tell your healthcare provider right away if you get a new or worsening skin rash or other signs of a severe skin reaction during treatment with UKONIQ, including:
    Painful sores or ulcers on your skin, lips, or in your mouth
    Rash with blisters or peeling skin
    Rash with itching
    Rash with fever

    If you have any of the above serious side effects during treatment with UKONIQ, your doctor may completely stop your treatment, stop your treatment for a period of time, or change your dose of UKONIQ.

    Before starting UKONIQ, tell your healthcare provider about all of your medical conditions, including if you:

    Have an infection
    Have abdominal or intestinal problems
    Have liver problems
    Are allergic to FD&C Yellow No. 5 (tartrazine) or aspirin. UKONIQ tablets contain FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain people, especially people who also have an allergy to aspirin.
    Are pregnant or plan to become pregnant. UKONIQ can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with UKONIQ.
    Females and males with female partners who are able to become pregnant should use effective birth control (contraception) during treatment with UKONIQ and for 1 month after the last dose of UKONIQ. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you or your partner become pregnant or think you are pregnant during treatment with UKONIQ.
    Are breastfeeding or plan to breastfeed. It is not known if UKONIQ passes into your breast milk. Do not breastfeed during treatment with UKONIQ and for 1 month after the last dose of UKONIQ.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    The most common side effects of UKONIQ include:

    Changes in certain kidney function blood tests
    Tiredness
    Nausea
    Muscle or bone pain
    Low red blood cell count (anemia)
    Low platelet count
    Upper respiratory tract infection
    Vomiting
    Abdominal pain
    Decreased appetite

    These are not all the possible side effects with UKONIQ. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

  • For important risk and use information about UKONIQ, please see the full Product Information.